ClinicalTrials.gg
Not yet recruitingNCT07843888Updated Nov 2, 2026

The Effectiveness of a Caregiver-Based Multicomponent Intervention to Prevent Pressure Ulcers in Home-Cared-For Individuals With Dementia

An interventional study of Pressure Injury Prevention Education in Dementia, Home Care for Elderly or Disabled Individuals and Decubitis Ulcer, sponsored by Manisa Celal Bayar University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Manisa Celal Bayar University · Not applicable, Interventional, and Prevention

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction and Aim: Pressure ulcers are preventable complications that are common, particularly in individuals with dementia cared for at home, reducing quality of life and creating significant costs for the healthcare system. The risk of pressure ulcers increases in individuals with dementia due to mobility limitations, communication difficulties, and caregiver dependency; in a home care setting, the knowledge and skill deficiencies of caregivers further exacerbate this risk. The aim of this study is to evaluate the effectiveness of a multi-component training, monitoring, and reminder intervention developed for caregivers of individuals with dementia cared for at home in reducing the risk of pressure ulcers and the development of new pressure ulcers compared to standard care.

This study goes beyond the predominantly institution- and hospital-based approaches in the literature on pressure ulcer prevention, offering a structured, experimental intervention model specific to individuals with dementia cared for at home and their caregivers. This study aims to present a caregiver-based, feasible, and low-cost model for the prevention of pressure ulcers in individuals with dementia receiving home care, and to contribute the findings to scientific publications and home care services. Method: The study was designed as a two-arm, parallel-group randomized controlled experimental design. Patient-caregiver pairs (PCGs) consisting of individuals diagnosed with dementia and their primary caregivers receiving home care were randomized into intervention and control groups. The intervention group (n=60) received a 12-week multi-component program consisting of structured training sessions for caregivers, daily pressure ulcer prevention checklists, weekly coaching sessions, and text message reminders. The control group (n=60) received standard care and general information. The primary outcomes of the project were pressure ulcer risk (Braden Pressure Ulcer Risk Assessment Scale) and the development of new pressure ulcers. Secondary outcomes included caregiver knowledge level, adherence to preventive care practices, and changes in caregiver burden. The obtained data were statistically analyzed.

02

Conditions studied

  • Dementia
  • Home Care for Elderly or Disabled Individuals
  • Decubitis Ulcer
  • Intervention
  • Multicomponent 12-week Program

Browse trials for

03

In context

Dementia

2,374 studies on the registry are indexed under Dementia; 574 are open to participants now.

This study's planned enrollment of 120 is above the median of 90 across 1,761 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Manisa Celal Bayar University is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals clinically diagnosed with dementia,
  • Home-cared for,
  • At risk of pressure ulcers (Braden Pressure Ulcer Risk Assessment Scale ≤18),
  • Having at least one primary caregiver, and the caregiver agreeing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of stage 3 or 4 pressure ulcer,
  • Hospitalisation within the last month.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Pressure Injury Prevention Education

    The intervention group (n=60) received a 12-week multi-component program consisting of structured training sessions for caregivers, daily pressure ulcer prevention checklists, weekly coaching sessions, and text message reminders.

    Behavioral: Pressure Injury Prevention Education

  • No intervention
    Usual Care

    Caregivers in the control group (n=60) will only receive a general informational brochure as part of standard care. No training or monitoring interventions will be applied to this group. In accordance with ethical principles, participants in the control group will also be provided with access to training materials after the study is completed.

Interventions

  • BehavioralPressure Injury Prevention Education

    Structured Training Sessions (The training program consists of the following main topics: Basic Knowledge of Pressure Ulcers Skin Assessment and Care Positioning Nutrition and Hydration Pressure Reduction), Daily Pressure Ulcer Prevention Checklist, Coaching and Follow-up Meetings, Reminder Messages

06

What researchers measure

Primary outcomes

  1. Braden Pressure Ulcer Risk Assessment Scale

    The Braden Scale for Predicting Pressure Sore Risk consists of six subscales: sensory perception, moisture, activity, mobility, nutrition, and friction/shear. The first five subscales are scored from 1 to 4, while friction/shear is scored from 1 to 3. Total scores range from 6 to 23, with lower scores indicating a higher risk of pressure injury. Scores of ≤12 indicate high risk, 13-14 moderate risk, and 15-16 low risk. For individuals aged 75 years or older, scores of 15-18 are considered indicative of low risk.

    Time frame: This will be evaluated with T0 (baseline), T1 (week 6) and T2 (week 12) measurements.

Secondary outcomes

  1. Zarit Burden Interview

    The scale consists of 22 items, each scored from 0 (never) to 4 (nearly always). The total score ranges from 0 to 88, with higher scores indicating greater caregiver burden.

    Time frame: Assessment will be based on T0 (baseline), T1 (week 6), and T2 (week 12) measurements.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Oct 2027, 5 months later.

Of 861 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 5 months is below that.

Counting every sponsor, half of 907 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Sep 2026 → May 2027 and primary completion Sep 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Sep 28, 2026
StartEst.
May 10, 2027was Sep 2026
Primary completionEst.
Oct 15, 2027was Sep 2026
CompletionEst.
Dec 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→May 10, 2027
Nov 2, 2026
Primary completion
Sep 2026→Oct 15, 2027
Nov 2, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 2, 2026
    Start date Sep 2026→May 10, 2027
    Primary completion Sep 2026→Oct 15, 2027
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843888
Lead sponsor
Manisa Celal Bayar University
Responsible party
Fatma Uyar Açışlı (Assistant Professor, Manisa Celal Bayar University) — Principal investigator
First posted
Sep 28, 2026
Start date
May 10, 2027 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion